Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology

被引:88
作者
D'Alto, Michele [1 ]
Romeo, Emanuele [1 ]
Argiento, Paola [1 ]
Sarubbi, Berardo [1 ]
Santoro, Giuseppe [1 ]
Grimaldi, Nicola [1 ]
Correra, Anna [1 ]
Scognamiglio, Giancarlo [1 ]
Russo, Maria Giovanna [1 ]
Calabro, Raffaele [1 ]
机构
[1] Univ Naples 2, Dept Cardiol, Monaldi Hosp, Naples, Italy
关键词
Pulmonary arterial hypertension; Congenital heart disease; Association therapy; IMPROVES FUNCTIONAL-CAPACITY; ORAL SILDENAFIL; COMBINATION THERAPY; INHALED ILOPROST; CLINICAL-TRIAL; ADULT PATIENTS; 6-MINUTE WALK; OPEN-LABEL; EFFICACY; TOLERABILITY;
D O I
10.1016/j.ijcard.2010.10.051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The aim of the present study was to evaluate the safety, tolerability, clinical and haemodynamic impact of add-on sildenafil in patients with congenital heart disease (CHD)-related pulmonary arterial hypertension (PAH) and Eisenmenger physiology after failure of oral bosentan therapy. Methods: Thirty-two patients with CHD-related PAH (14 male, mean age 37.1 +/- 13.7 years) treated with oral bosentan underwent right heart catheterization (RHC) for clinical worsening. After RHC, all patients received oral sildenafil 20 mg thrice daily in addition to bosentan. Clinical status, resting transcutaneous oxygen saturation (SpO(2)), 6-minute walk test (6MWT), serology and RHC were assessed at baseline (before add-on sildenafil) and after 6 months of combination therapy. Results: Twelve patients had ventricular septal defect, 8 atrio-ventricular canal, 6 single ventricle, and 6 atrial septal defect. Twenty-eight/32 had Eisenmenger physiology and 4 (all with atrial septal defect) did not. All patients well tolerated combination therapy. After 6 months of therapy, an improvement in clinical status (WHO functional class 2.1 +/- 0.4 vs 2.9 +/- 0.3; P=0.042), 6-minute walk distance (360 +/- 51 vs 293 +/- 68 m; P=0.005), SpO(2) at the end of the 6MWT (72 +/- 10 vs 63 +/- 15%; P=0.047), Borg score (2.9 +/- 1.5 vs 4.4 +/- 2.3; P=0.036), serology (pro-brain natriuretic peptide 303 +/- 366 vs 760 +/- 943 pg/ml; P=0.008) and haemodynamics (pulmonary blood flow 3.4 +/- 1.0 vs 3.1 +/- 1.2 l/min/m(2), P=0.002; pulmonary vascular resistances index 19 +/- 9 vs 24 +/- 16 WU/m(2), P=0.003) was observed. Conclusions: Addition of sildenafil in adult patients with CHD-related PAH and Eisenmenger syndrome after oral bosentan therapy failure is safe and well tolerated at 6-month follow-up, resulting in a significant improvement in clinical status, effort SpO(2), exercise tolerance and haemodynamics. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:378 / 382
页数:5
相关论文
共 37 条
[1]   Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study [J].
Apostolopoulou, S. C. ;
Manginas, A. ;
Cokkinos, D. V. ;
Rammos, S. .
HEART, 2007, 93 (03) :350-354
[2]   Pulmonary Arterial Hypertension Baseline Characteristics From the REVEAL Registry [J].
Badesch, David B. ;
Raskob, Gary E. ;
Elliott, C. Greg ;
Krichman, Abby M. ;
Farber, Harrison W. ;
Frost, Adaani E. ;
Barst, Robyn. J. ;
Benza, Raymond L. ;
Liou, Theodore G. ;
Turner, Michelle ;
Giles, Scott ;
Feldkircher, Kathy ;
Miller, Dave P. ;
McGoon, Michael D. .
CHEST, 2010, 137 (02) :376-387
[3]   Eisenmenger Syndrome A Clinical Perspective in a New Therapeutic Era of Pulmonary Arterial Hypertension [J].
Beghetti, Maurice ;
Galie, Nazzareno .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (09) :733-740
[4]   Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease [J].
Benza, RL ;
Rayburn, BK ;
Tallaj, JA ;
Coffey, CS ;
Pinderski, LJ ;
Parnoukian, SV ;
Bourge, RC .
CHEST, 2006, 129 (04) :1009-1015
[5]   Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension [J].
Chau, Elaine M. C. ;
Fan, Katherine Y. Y. ;
Chow, W. H. .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 120 (03) :301-305
[6]   Ethical authorship and publishing [J].
Coats, Andrew J. S. .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2009, 131 (02) :149-150
[7]   Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology):: safety, tolerability, clinical, and haemodynamic effect [J].
D'Alto, M. ;
Vizza, C. D. ;
Romeo, E. ;
Badagliacca, R. ;
Santoro, G. ;
Poscia, R. ;
Sarubbi, B. ;
Mancone, M. ;
Argiento, P. ;
Ferrante, F. ;
Russo, M. G. ;
Fedele, F. ;
Calabro, R. .
HEART, 2007, 93 (05) :621-625
[8]   Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease [J].
Diller, Gerhard-Paul ;
Dimopoulos, Konstantinos ;
Kaya, Mehmet G. ;
Harries, Carl ;
Uebing, Anselm ;
Li, Wei ;
Koltsida, Evdokia ;
Gibbs, J. Simon R. ;
Gatzoulis, Michael A. .
HEART, 2007, 93 (08) :974-976
[9]   Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study [J].
Diller, Gerhard-Paul ;
Dimopoulos, Konstantinos ;
Broberg, Craig S. ;
Kaya, Mehmet G. ;
Naghotra, Utpal Singh ;
Uebing, Anselm ;
Harries, Carl ;
Goktekin, Omer ;
Gibbs, J. Simon R. ;
Gatzoulis, Michael A. .
EUROPEAN HEART JOURNAL, 2006, 27 (14) :1737-1742
[10]   Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications [J].
Dimopoulos, Konstantinos ;
Giannakoulas, Georgios ;
Wort, Stephen John ;
Gatzoulis, Michael A. .
CURRENT OPINION IN CARDIOLOGY, 2008, 23 (06) :545-554